DCST2

Across TCGA pan-cancer cohorts, DCST2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DCST2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DCST2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DCST2 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

HNSC, BLCA, and SARC are the cancer types where DCST2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.156	0.710	.006	12	view →
BLCA	DFS	Median	All	1.000	0.328	.025	12	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DCST2–HNSC (DFS)

Open the HNSC breakdown →